Figure 7.

ZA and Tα1 treatment alters the tumor immune landscape by modulating the MyD88/NF-κB pathway in vivo. (A) IHC staining of MyD88 and p-NF-κB in PCa RM-1 tumors from mice treated with vehicle, ZA, Tα1, or ZA+Tα1. Quantification of the IHC staining is shown. Scale bar: 50 µm. (B, C) IF staining of (B) F4/80⁺MyD88⁺ and F4/80⁺p-NF-κB⁺ TAMs and (C) CD8⁺MyD88⁺ and CD8⁺p-NF-κB⁺ T cells in PCa RM-1 tumors from mice treated with ZA and/or Tα1. Scale bar: 20 µm. Quantification of the IF staining is shown. Data are presented as mean±SEM. n=5. ^*P<0.05, ^**P<0.01, and ^***P<0.001. IF, immunofluorescence; IHC, immunohistochemical; PCa, prostate cancer; TAM, tumor-associated macrophage; Tα1, thymosin α1; ZA, zoledronic acid.